article thumbnail

This Common Artificial Sweetener Can Break Down DNA, Scientists Warn

AuroBlog - Aurous Healthcare Clinical Trials blog

The artificial sweetener sucralose (marketed as Splenda) is widely used and found in products like diet soda and chewing gum. According to a new study, it’s also capable of damaging the DNA material inside our cells.

DNA 245
article thumbnail

Tripartite MoU signed for mRNA production platform in Egypt

Pharmaceutical Technology

EVA Pharma of Africa, DNA Script and Quantoom Biosciences have signed a MoU to establish the mRNA production platform in Egypt.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Blocking DNA production in cancer therapy by targeting the POLtheta enzyme

Medical Xpress

BRCA1 (BReast CAncer Gene 1), a key gene that becomes faulty in some instances, leading to breast and ovarian cancer, plays an important role in the body's DNA repair mechanisms. BRCA1, once mutated, can cause cancer to develop.

DNA 116
article thumbnail

Logistics in Focus: Orchestrating the Challenges of Cell Therapy

Worldwide Clinical Trials

For example, once considered incurable and terminal, patients with sickle cell disease may reach new summits in their lives with gene editing technologies such as CRISPR to repair affected DNA and, in some cases, functionally cure the condition. These advanced therapeutics harness the power of molecular biology to improve human health.

article thumbnail

GE Research Picks DNA Script to Join On-Demand Vaccine Production Collaboration

BioSpace

GE Research selected DNA Script to join a collaboration working on a rapid response, mobile platform to develop on-demand production of nucleic acid-based vaccines and therapies related to biological threats.

DNA 96
article thumbnail

DNA production specialist Touchlight raises £42m

Pharma Times

Proceeds will be used to ‘more than triple’ UK biotech's manufacturing capabilities

DNA 123
article thumbnail

STAT+: Pacific Biosciences, known for niche DNA sequencing, looks to rival Illumina with new product launch

STAT News

firm best known for its niche approach to DNA sequencing, on Tuesday announced plans to launch a new product that will put the company in direct competition with genomics juggernaut Illumina. The new DNA sequencer, dubbed Onso, reads the genome in small pieces and uses software to stitch that information together.

DNA 98